Literature DB >> 11139795

Gene therapy for vein graft disease.

D G Cable1, H V Schaff.   

Abstract

Applying gene therapeutics to vein graft disease requires foundational knowledge of the underlying pathophysiology. This review details a brief description of vein graft disease, examines published and unpublished data on gene transfer to veins, and reviews the genes, which have significantly altered vascular biology.

Entities:  

Mesh：

Year:  2001        PMID： 11139795     DOI： 10.1007/s11886-001-0006-0

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  40 in total

1.  The role of gene therapy for intimal hyperplasia of bypass grafts.

Authors:  D G Cable; J A Caccitolo; N Caplice; T O'Brien; R D Simari; R C Daly; J A Dearani; C J Mullany; T A Orszulak; H V Schaff
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

2.  Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts.

Authors:  L B Schwartz; J Moawad; E C Svensson; R L Tufts; S L Meyerson; D Baunoch; J M Leiden
Journal:  J Vasc Surg       Date:  1999-05       Impact factor: 4.268

3.  Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.

Authors:  S Goldman; J Copeland; T Moritz; W Henderson; K Zadina; T Ovitt; J Doherty; R Read; E Chesler; Y Sako
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

4.  Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels.

Authors:  K M Channon; G J Fulton; J L Gray; B H Annex; G A Shetty; M A Blazing; K G Peters; P O Hagen; S E George
Journal:  Cardiovasc Res       Date:  1997-09       Impact factor: 10.787

5.  Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins.

Authors:  S J George; A H Baker; G D Angelini; A C Newby
Journal:  Gene Ther       Date:  1998-11       Impact factor: 5.250

6.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.

Authors:  M J Mann; A D Whittemore; M C Donaldson; M Belkin; M S Conte; J F Polak; E J Orav; A Ehsan; G Dell'Acqua; V J Dzau
Journal:  Lancet       Date:  1999-10-30       Impact factor: 79.321

7.  Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model.

Authors:  D G Neschis; S D Safford; A K Hanna; J C Fox; M A Golden
Journal:  J Vasc Surg       Date:  1998-01       Impact factor: 4.268

8.  Adenoviral-mediated inhibition of G beta gamma signaling limits the hyperplastic response in experimental vein grafts.

Authors:  T T Huynh; G Iaccarino; M G Davies; E Svendsen; W J Koch; P O Hagen
Journal:  Surgery       Date:  1998-08       Impact factor: 3.982

9.  Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit.

Authors:  L J Feldman; P G Steg; L P Zheng; D Chen; M Kearney; S E McGarr; J J Barry; J F Dedieu; M Perricaudet; J M Isner
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model.

Authors:  J M Waugh; E Yuksel; J Li; M D Kuo; M Kattash; R Saxena; R Geske; S N Thung; S M Shenaq; S L Woo
Journal:  Circ Res       Date:  1999 Jan 8-22       Impact factor: 17.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.